Latest news with #patent
Associated Press
2 days ago
- Business
- Associated Press
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN ) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, 'Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models.' This patent covers technology developed by that leverages machine learning algorithms, powered by Microsoft (Nasdaq: MSFT ) and Databricks intended to rapidly and accurately identify peptides with strong immune system interactions. Identifying these peptides is critical in developing targeted therapies for a variety of diseases, including cancers and infectious diseases. Traditional methods for identifying immunologically active peptides often face significant limitations, such as overlooking critical human genetic diversity factors like age, sex, race, and ethnicity. proprietary approach may overcome these challenges by: 'I'm pleased with continued progress in strategically harnessing artificial intelligence in support of our cell therapy development,' said Dr. Ryan Saadi, Founder and CEO of Tevogen. 'Leveraging AI to accelerate discovery, shorten development timelines, and reduce costs is essential to our mission of delivering commercially attractive, economically viable, and cost-effective personalized T cell therapies.' Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 [email protected]
Yahoo
2 days ago
- Business
- Yahoo
Lisata Secures New Composition of Matter Patent for Certepetide
By Daniella Parra Lisata Therapeutics said it has been granted a new composition of matter patent for its lead drug candidate, certepetide, offering the highest level of IP protection by covering the drug's unique chemical structure, how it's made, and how it's used to treat solid tumor cancers, they said. Certepetide is an investigational peptide drug developed to improve the delivery of anti-cancer therapies into solid tumors, the company said. 'This new patent marks a key milestone, significantly boosting the value of both certepetide and the Company by delaying generic encroachment for essentially the next two decades,' stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata. '[It] greatly strengthens our negotiating position with potential partners, increasing the potential for sustained growth and value creation for our shareholders.' READ MORE HEALTHCAREEDGE Lisata Therapeutics Reports Trial Results for Pancreatic Cancer Treatment Register for our weekly newsletter Contact: Exec Edge Editor@ Click to follow us on LinkedIn
Yahoo
3 days ago
- Business
- Yahoo
Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to pay patent fee
In what Science magazine has dubbed 'Novo Nordisk's Canadian Mistake,' Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly failed to pay a few hundred dollars in annual fees to maintain the patent rights before the weight-loss drug became a blockbuster seller. As Science reported, a patent, once lapsed, can't be restored. Novo Nordisk will continue to hold its U.S. patent until 2032. Ozempic was already the third most prescribed drug in Canada last year with 7,390,000 prescriptions dispensed, a 17 per cent increase over 2023, according to drug analytics research firm IQVIA. Several applications for generic semaglutide, the active compound in Novo Nordisk's injectable drugs Ozempic and Wegovy, are now before Health Canada. Last week, a U.S. telehealth service announced plans to expand into Canada next year and offer generic semaglutide at a significant discount. Richard Saynor, the head of Sandoz, a global leader in generic and biosimilar drugs, told Endpoint News in June that his company has filed for approval for a generic semaglutide in Canada once Novo Nordisk's patent exclusivity expires 'sometime in Q1 next year.' Canada is the globe's second-biggest semaglutide market, Saynor told Endpoint News. 'You gotta ask why. I don't think Canadians are disproportionately large. There's clearly a dynamic, like insulin, with cross-border business,' he said. Americans with diabetes have crossed into Canada to buy insulin at much lower prices. Ozempic and Wegovy cost about $5,000 per year. If money is no longer a factor, if chemically-identical drugs are cheaper and more affordable, 'that's going to change the calculus for many people,' said Justin Lehmiller, a senior research fellow at Indiana University's Kinsey Institute and co-author of a new survey exploring the impact that weight-loss drugs — formally known as GLP-1 agonists — are having on dating and intimacy. The survey of 2,000 single Americans (aged 18 to 91) led by Kinsey with found eight per cent reported having used a GLP-1 medication for weight loss in the past year. Among the GLP-1 users, 16 per cent said exes had reached out to reconnect, 14 per cent said they were getting more matches on dating apps and 12 per cent said they were going on more dates. The drugs seemed to be doing more to booster 'online dating success' for men than for women, the researchers said. 'Some of the studies and research that I've seen suggest that men only match one in 100 times on dating apps where for women, it's more like one in 10,' Lehmiller said. 'An attractiveness boost for men, which often accompanies using these drugs, could translate into a much bigger impact for them in the world of dating.' Men, however, were nearly twice as likely to women to say they feared being judged or shamed for taking Ozempic or other GLP-1 drugs. 'There are some masculinity concerns that are tied up in this,' said Lehmiller, a social psychologist. Men might worry about being accused of cheating, he said. 'It might be viewed as a sign of weakness for turning to a drug as opposed to losing weight through 'hard work.'' About half of the GLP-1 users also said the medications impact their sex lives, in both positive and negative ways: 18 per cent said their sexual desire increased, while 16 per cent said it dropped. Sixteen per cent said their sexual function improved; 12 per cent said it worsened. It's a nuanced picture, Lehmiller said. 'These drugs seem to be affecting different people in different ways.' 'And I think that makes sense: There is a lot of variability in the side effects people experience on these drugs.' More side effects might mean more negative impact on intimacy, he said. The drugs have also been associated with a slightly higher risk of erectile dysfunction and testosterone deficiency in men taking semaglutide for obesity compared to men not taking the drug. About one in five in the dating survey said the drugs are creating more stigma against being overweight. 'Changing standards of attractiveness might be creating more pressure for people to look a certain way or use these medications,' Lehmiller said. A study published this week in the Canadian Medical Association Journal found 32.7 per cent of adults in Canada (10.6 million people) were obese in 2023, an eight per cent jump over 2009. Generic semaglutide won't be as cheap as Aspirin. 'It's still going to be a cost,' said Dr. Hertzel Gerstein, an endocrinologist and professor in McMaster University's department of medicine. 'And that does not relieve a responsible health practitioner of assessing a patient before they prescribe the medication,' he said. 'Is it possible that more people would be willing to pay out of pocket if they don't have insurance coverage for the drug? Sure, if it's cheaper,' Gerstein said. 'There may be more demand for it. People need to understand the risks and benefits.' Taken once a week by injection, Ozempic and Wegovy work by mimicking a hormone — glucagon-like peptide-1 — the small intestine releases when people eat. GLP-1 tricks the body into thinking it's full. It works on the brain to reduce appetite and interest in continuing to eat, and works on the stomach to slow how fast it empties so that food lingers in the stomach longer. Semaglutide has been studied extensively, Gerstein said. The amount of weight lost is related to the dosage: the higher the dose, the more weight dropped. In people with type 2 diabetes, the drug can reduce the need for insulin, or the dosage. 'But most importantly these drugs unequivocally reduce the future risk of serious health outcomes, including heart attacks, strokes, death from cardiovascular causes' and heart failure symptoms when used long-term, 'in the two- to five-year window of time,' Gerstein said. A major analysis published earlier this year based on health data from more than two million Americans veterans with diabetes found that, compared to more traditional drugs, GLP-1 use was associated with a reduced risk of substance use (alcohol, cannabis, stimulants and opioids), psychotic disorders such as schizophrenia, seizures, several respiratory conditions and neurocognitive diseases like Alzheimer's and dementia. The magnitude of the associated benefits — about a 10 to 20 per cent reduction for most outcomes — was modest, according to a background release, though the researchers said they don't 'negate' the potential value of the drugs. There were, however, several drawbacks, including an increased risk of gastrointestinal disorders (nausea, vomiting, diarrhea), low blood pressure, fainting, arthritic disorders, kidney disorders and drug-induced pancreatitis associated with GLP-1 drugs compared to usual care. Nothing is guaranteed, Gerstein said. 'I always tell patients we don't know exactly what it'll do in you. And weight loss, if it's going to happen, usually takes a month or two to start' and plateaus at around eight months. People don't lose weight indefinitely. 'There's definitely a plateau. You do not keep losing weight,' he said. The drugs yield an average weight loss of around 15 per cent, and weight can also rebound rapidly once the drugs are stopped. Ozempic has been approved in Canada for diabetes but is often used 'off label' for obesity. Wegovy has been approved for obesity. In an email to National Post, Novo Nordisk, the only current company in Canada with Health Canada-approved products containing semaglutide, said 'all intellectual property decisions are carefully considered at a global level. 'Periods of exclusivity for pharmaceutical products end as part of their normal lifecycle and generic treatments may become available over time,' the company said. 'Currently, no Health Canada-approved generic versions of semaglutide exist and we cannot speculate on other manufacturers' plans,' it added. National Post Ozempic for kids? Doctors are being encouraged to offer weight-loss drugs to Canadian teens 'It's not going away': How weight-loss drugs like Ozempic are changing the food industry Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our newsletters here.
National Post
4 days ago
- Health
- National Post
Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to maintain patent in this country
In what Science magazine has dubbed 'Novo Nordisk's Canadian Mistake,' Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly failed to pay a few hundred dollars in annual fees to maintain the patent rights before the weight-loss drug became a blockbuster seller. Article content As Science reported, a patent, once lapsed, can't be restored. Novo Nordisk will continue to hold its U.S. patent until 2032. Article content Article content Ozempic was already the third most prescribed drug in Canada last year with 7,390,000 prescriptions dispensed, a 17 per cent increase over 2023, according to drug analytics research firm IQVIA. Article content Article content Several applications for generic semaglutide, the active compound in Novo Nordisk's injectable drugs Ozempic and Wegovy, are now before Health Canada. Last week, a U.S. telehealth service announced plans to expand into Canada next year and offer generic semaglutide at a significant discount. Article content Richard Saynor, the head of Sandoz, a global leader in generic and biosimilar drugs, told Endpoint News in June that his company has filed for approval for a generic semaglutide in Canada once Novo Nordisk's patent exclusivity expires 'sometime in Q1 next year.' Canada is the globe's second-biggest semaglutide market, Saynor told Endpoint News. 'You gotta ask why. I don't think Canadians are disproportionately large. There's clearly a dynamic, like insulin, with cross-border business,' he said. Americans with diabetes have crossed into Canada to buy insulin at much lower prices. Article content Ozempic and Wegovy cost about $5,000 per year. If money is no longer a factor, if chemically-identical drugs are cheaper and more affordable, 'that's going to change the calculus for many people,' said Justin Lehmiller, a senior research fellow at Indiana University's Kinsey Institute and co-author of a new survey exploring the impact that weight-loss drugs — formally known as GLP-1 agonists — are having on dating and intimacy. Article content The survey of 2,000 single Americans (aged 18 to 91) led by Kinsey with found eight per cent reported having used a GLP-1 medication for weight loss in the past year. Article content Among the GLP-1 users, 16 per cent said exes had reached out to reconnect, 14 per cent said they were getting more matches on dating apps and 12 per cent said they were going on more dates. The drugs seemed to be doing more to booster 'online dating success' for men than for women, the researchers said. Article content 'Some of the studies and research that I've seen suggest that men only match one in 100 times on dating apps where for women, it's more like one in 10,' Lehmiller said. 'An attractiveness boost for men, which often accompanies using these drugs, could translate into a much bigger impact for them in the world of dating.'
Reuters
4 days ago
- Business
- Reuters
Novartis cannot block generic version of Entresto, judge rules
July 16 (Reuters) - A federal judge rejected Novartis' (NOVN.S), opens new tab request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the blockbuster heart medication Entresto. In a decision on Tuesday, U.S. District Judge Evelyn Padin in Newark, New Jersey also reversed her prior ruling that Novartis would likely succeed on its claim of trade dress infringement against the defendant MSN proposed selling a generic version of Entresto under the name Novadoz, which blends the names of Novartis and its Sandoz generics unit. Padin also said Novartis' exclusivity over Entresto may not continue indefinitely, and that "denial of injunctive relief and the availability of a generic alternative to a life-savings medication is in the public interest." Novartis and its lawyers did not immediately respond to requests for comment on Wednesday. The judge said its patent-related exclusivity expires today, July 16.
